Company Overview and News

4
Sensex, Nifty turn choppy on global rising trade war concerns

12h freepressjournal.in
Mumbai: Benchmark indices turned volatile in early trade Tuesday on escalating global trade concerns after US President Donald Trump announced new tariffs on an additional USD 200 billion worth of imports from China.
500820 BHRQY ASIANPAINT 500470 532121 HEROMOTOCO 500570 BHARTIARTL TATAMOTORS YESBANK IBN 532648 YYBKY 532401 VIJAYABANK 500182 532454 ICICIBANK TTST TATASTEEL TATLY 532174 HRTQY DENABANK TTM

 
Asian Paints, Kansai Nerolac down 1-2% despite Citi remains positive on revenue growth prospects

2018-09-17 moneycontrol
Paint companies including Asian Paints and Kansai Nerolac Paints were down 1-2 percent despite research house Citi remained positive on revenue growth prospects of Indian paints industry.
500820 KANSAINER KNZAY ASIANPAINT 500165

 
D-Street Buzz: PSU banks drag as BoB falls 2%; Weak rupee helps IT stocks gain led by Mindtree

2018-09-17 moneycontrol
The Indian stock market are trading on a weak note this Monday morning with the Nifty50 down 110 points and is trading at 11,404 while the Sensex is trading lower by 361 points at 37,729.
IOC 500325 500820 500547 533271 RELIANCE TCHQY 532538 ASHOKA 532755 ASIANPAINT 535789 505200 532461 INOXWIND RIGD UCLQY JSL EICHERMOT UNIVCABLES RLNIY 504212 SBAZ ECQRY UBNC BPCL 532508 IDKQY CANFINHOME UCLQF 511196 530965 ULTRACEMCO TECHM IBULHSGFIN PNJZY BRQPY PNB HINDPETRO 500104 539083

 
Asian Paints Limited - Trading Window

2018-09-14 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
500820 ASIANPAINT

 
Asian Paints Limited - Updates

2018-09-11 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
500820 ASIANPAINT

 
Asian Paints Limited - Analysts/Institutional Investor Meet/Con. Call Updates

2018-09-07 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
500820 ASIANPAINT

5
Sensex drops 140 points as rupee hits new low

2018-09-05 freepressjournal.in
Mumbai: Falling for the sixth straight session, the BSE Sensex shed about 140 points Wednesday to close at an over two-week low of 38,018.31 as investor sentiment remained bearish amid a plunging rupee and weak global cues. The rupee crashed to a fresh record low of 71.96 against the US dollar in intra-day trade on the back of rising bond yields and crisis in emerging market currencies. Market sentiment was further dampened after a monthly survey showed that India’s services sector activity fell in August from July’s 21-month peak as new business orders declined.
BAJAJ-AUTO 500820 532977 BHRQY ASIANPAINT 533278 532215 500470 532187 AXISBANK HDFCBANK HEROMOTOCO 500570 BHARTIARTL TATAMOTORS CLNDY YESBANK AXB INDUSINDBK IBN 532648 YYBKY AXBKY 500182 532454 AXBA ICICIBANK TTST TATASTEEL TATLY HDB 532174 500180 HRTQY COALINDIA TTM

 
Podcast | Digging Deeper- The Asian Paints story: Colour-coding the success mantra

2018-09-05 moneycontrol
"Har Ghar Kuch Kehta hi,” says the Asian Paints punch line and it in a way sums up the brand's lasting relationship with the Indian consumer.
SOMANYCERA 500820 PPG 531548 ASIANPAINT

 
Asian Paints (ASNQY) Investor Presentation - Slideshow

2018-09-04 seekingalpha
The following slide deck was published by Asian Paints India Ltd. ADR in conjunction with this event.
ASNQY 500820 ASIANPAINT

5
Sensex falls for 5th day on rising crude prices, rupee woes

2018-09-04 freepressjournal.in
New Delhi: The benchmark BSE Sensex Tuesday lost about 155 points to close at an over two-week low of 38,157.92, falling for the fifth session in a row following sustained foreign fund outflows, surging global crude oil prices and tumbling rupee against dollar.
BAJAJ-AUTO 500820 532977 BHRQY ASIANPAINT TTNQY 533278 500470 532540 532187 HDFCBANK HEROMOTOCO 500570 BHARTIARTL TATAMOTORS CLNDY YESBANK INDUSINDBK IBN 532648 YYBKY 500182 532454 ICICIBANK TTST TATASTEEL TATLY HDB 532174 500180 TCS HRTQY COALINDIA TTM

 
An evening walk down Dalal Street | Higher Brent crude prices, weak rupee weigh on Sensex, Nifty; IT stocks surge

2018-09-04 moneycontrol
It was a double whammy for the market on Tuesday as a weak rupee along with higher crude oil prices dragged the market further. The Nifty managed to give up 11,550-mark, while the Sensex shed 38,200-mark as well.
BALKRISIND 532540 500820 FORCEMOT TCHQY TCS ASIANPAINT TTNQY 532755 500033 502355 TECHM

Related Articles

RIGL: Rigel Pharmaceuticals Analysis and Research Report

11h - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...

EKSO: Ekso Bionics Holdings Analysis and Research Report

11h - Asif

Overview The company design, develop and sell exoskeleton technology to augment human strength, endurance and mobility. The company's exoskeleton technology serves multiple markets and can be used both by able-bodied users as well as by persons with physical disabilities. Ekso Bionics has sold, rented or leased devices that (a) enable individuals with neurological conditions affecting gait (stroke and spinal cord injury) to rehabilitate and to walk again and (b) allow industrial workers to perform heavy duty work for extended periods. Today, its medical exoskeleton, Ekso GT, is used as a rehabilitation tool to allow physicians and therapists to rehabilitate patients who have suffered a stroke or spinal cord injury. With its unique features designed specifically for hospitals and its proprietary SmartAssist software, Ekso GT allows for the early mobilization of patients, with high step count and high dosage treatments. The intent is to allow the patient’s central nervous syst...

AGRX: Agile Therapeutics Analysis and Research Report

13h - Asif

Overview Agile Therapeutics is a forward-thinking women’s healthcare company dedicated to fulfilling the unmet health needs of today’s women. Twirla® and its other current potential product candidates are designed to provide women with contraceptive options that offer greater convenience and facilitate compliance. The company's lead product candidate, Twirla, also known as AG200-15, is a once-weekly prescription contraceptive patch that is at the end of Phase 3 clinical development. Since its inception in 1997, Agile Therapeutics has devoted substantial resources to developing Twirla, building its intellectual property portfolio, business planning, raising capital and providing general and administrative support for these operations. The company incurred research and development expenses of $14.4 million, $20.9 million and $25.6 million during the years ended December 31, 2017, 2016 and 2015, respectively. The company incurred research and development expenses of $2.4 milli...